Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Z102-E
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Z102-E is a purified active substance derived from the bacterium *Lactiplantibacillus plantarum* strain Z102. It is being investigated as a natural bacteriostatic agent with anti-biofilm properties, particularly against the pathogenic bacterium *Listeria monocytogenes*. The proposed mechanism of action involves the downregulation of genes related to bacterial quorum sensing and biofilm formation, which reduces bacterial growth, motility, and the formation of protective biofilms. Currently, Z102-E is in the preclinical research phase and appears to be under investigation by academic institutions in China, with no specific commercial developer identified in the available literature.
Beyond the preview
Go deeper on Z102-E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Z102-E.